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The Ts65Dn mouse is the most studied animal model of Down syndrome. Past research has shown a significant reduction in CA1
hippocampal long-term potentiation (LTP) induced by theta-burst stimulation (TBS), but not in LTP induced by high-frequency
stimulation (HFS), in slices from Ts65Dn mice compared with euploid mouse-derived slices. Additionally, therapeutically relevant
doses of the drug memantine were shown to rescue learning and memory deficits in Ts65Dn mice. Here, we observed that 1μM
memantine had no detectable effect on HFS-induced LTP in either Ts65Dn- or control-derived slices, but it rescued TBS-
induced LTP in Ts65Dn-derived slices to control euploid levels. Then, we assessed LTP induced by four HFS (4xHFS) and
found that this form of LTP was significantly depressed in Ts65Dn slices when compared with LTP in euploid control slices.
Memantine, however, did not rescue this phenotype. Because 4xHFS-induced LTP had not yet been characterized in Ts65Dn
mice, we also investigated the effects of picrotoxin, amyloid beta oligomers, and soluble recombinant human prion protein
(rPrP) on this form of LTP. Whereas ≥10μM picrotoxin increased LTP to control levels, it also caused seizure-like oscillations.
Neither amyloid beta oligomers nor rPrP had any effect on 4xHFS-induced LTP in Ts65Dn-derived slices.
1. Introduction
Down syndrome (DS) is the set of phenotypic features of var-
iable expressivity that results from an extra copy of chromo-
some 21 (trisomy 21) and is the most common genetically
defined cause of intellectual disability [1, 2]. Persons with
DS typically display moderate intellectual disability [3], with
disproportionate deficits in hippocampus-dependent and
executive functions [4–6]. Individuals with DS exhibit a neu-
ropathology indistinguishable from Alzheimer disease (AD)
by age 40 [7] and high prevalence of early-onset dementia
in their fifth and sixth decades of life [8].
The Ts65Dn mouse is the most widely researched mouse
model for DS and the most complete in terms of displaying
phenotypes mimicking what is observed in persons with DS
(for reviews see [9, 10]). In attempts to understand the neu-
robiological basis for the cognitive deficits associated with
DS, much emphasis has been placed on the study of synaptic
plasticity in these animals, mostly long-term potentiation
(LTP), and, to a smaller extent, long-term depression
(LTD). This is because these forms of synaptic plasticity are
thought to engage some of the major cellular and circuit-
level mechanisms underlying learning and memory [11, 12].
Using brain slice techniques, Kleschevnikov et al. [13]
were the first to demonstrate significant deficits in the induc-
tion of LTP in the dentate gyrus of Ts65Dn mice, whereas
Costa and Grybko [14] were the first to show unequivocally
LTP deficits in the CA1 region of the hippocampus. Siarey
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et al. [15, 16] were the first to demonstrate enhanced levels of
CA1 LTD in Ts65Dn mice, and Scott-McKean and Costa
[17] established that this phenomenon is associated with N-
methyl-D-aspartic acid (NMDA) receptor dysfunction in
these animals.
LTP can be induced by a large number of electrical and
pharmacological stimulation protocols, which may be
custom-tailored by an individual research group to answer
very specific questions about synaptic plasticity mechanisms
in a given system. For the purposes of surveying the general
integrity of synaptic plasticity in hippocampal slices from
mouse models of neurological and psychiatric disorders,
however, three broad categories of induction protocols can
capture the most significant features one typically associates
with LTP. The first protocol involves a single high-
frequency stimulation (HFS); generally, a train of stimuli
applied at high frequency designed to produce a strong
tetanic stimulation of a single synaptic pathway. In the Schaf-
fer collateral pathway in the CA1 region of the hippocampus,
such modality of LTP is NMDA receptor-dependent, entails
the activation of CaMKII and PKC, is independent of pro-
tein synthesis, and lasts at most for a few hours [18, 19].
Although Siarey et al. [20] had initially observed a deficit
in such form of CA1 LTP in Ts65Dn mice compared with
euploid control mice, additional studies, beginning with
Costa and Grybko [14], found that this form of LTP is
unaffected in Ts65Dn mice.
The second commonly used LTP induction protocol
involves multiple short bursts of 3-4 stimuli separated by
a fixed interval designed to mimic the physiological situa-
tion in which presynaptic cells generate short bursts of
synaptic activity driven by an underlying circuit activation
pattern, typically a theta-frequency wave. The LTP result-
ing from such theta-burst stimulation (TBS) induction
protocol has many of the characteristics of HFS. However,
because of the 200-millisecond intervals between bursts of
stimulation, it is thought to be more dependent on the
activation of GABAergic interneurons than HFS [21].
Costa and Grybko [14] observed a small but significant
reduction on the levels of CA1 LTP induced by TBS in
hippocampal slices from Ts65Dn mice compared with
euploid control mice.
The third CA1 LTP induction protocol involves the use
of multiple (typically 3 or 4) HFS separated by an interval
of a few minutes, which produces a robust and long-lasting
(days, weeks, or months) enhancement in synaptic transmis-
sion. The resulting late-phase LTP (L-LTP) requires gene
transcription and protein synthesis in the postsynaptic neu-
ron [22]. Therefore, this form of LTP can be seen as an infor-
mative assay of the integrity of the essential transcriptional
and translational machinery in neuronal cells.
In the present study, we probed the three modalities of
CA1 LTP described above in hippocampal slices derived
from Ts65Dn and euploid control mice. The reason to
revisit the first two forms of LTP in these mice was to
investigate whether therapeutically relevant levels of the
uncompetitive NMDA receptor antagonist, memantine,
could interfere with the properties of either of these
NMDA receptor-dependent phenomena.
We found this investigation to be highly relevant to
broaden our understanding of the role of NMDA receptor
dysfunction in the pathogenesis of DS, particularly in light
of work showing that memantine can rescue learning and
memory deficits in Ts65Dn mice [23–25]. In addition, this
drug was also shown to rescue the exaggerated levels of
NMDA receptor-dependent CA1 LTD in Ts65Dn mice
[17]. These preclinical data led to the design of a pilot clinical
trial of memantine aiming at enhancing the cognitive abilities
of individuals with DS [26] and a follow-up, Phase II
clinical trial of memantine in adolescents and young adults
with DS (“NCT02304302” at http://www.clinicaltrials.gov),
which is underway.
LTP induced by multiple HFS in CA1 hippocampal slices
(and the resulting L-LTP) had not yet been characterized in
Ts65Dn mice. Therefore, in addition to testing the effects of
memantine, we decided to expand our investigation to
include three additional molecules of interest to the study
of DS that could potentially shed some light on this specific
form of LTP in Ts65Dn mice: (1) picrotoxin; (2) amyloid
beta (Aβ) oligomers; and (3) soluble (membrane anchor-
free) recombinant human prion protein (rPrP).
2. Materials and Methods
2.1. Animals. The original production of the segmental
trisomy Ts65Dn has been well described in the literature
[27]. Experimental mice were generated by repeated back-
crossing of Ts65Dn females to C57BL/6JEiJ×C3Sn.BLiA-
Pde6b+/D F1 hybrid males (as described in [28]) at the Case
Western Reserve University’s Animal Resource Center. Male
euploid littermates of Ts65Dn mice were used as controls.
Animals from the same litter and sex were housed in the
same cage and maintained in a 12 : 12-hour light/dark sched-
ule (lights on at 6:00 a.m.) with ad libitum access to food and
water. Adult male Ts65Dn and euploid littermate controls
age 6–9 months were used in the experiments described here.
All experimental methods have received the approval from
the Case Western Reserve University’s Animal Care and
Use Committee.
2.2. Slice Preparation. Mice were decapitated under halo-
thane anesthesia and their brains were rapidly harvested for
dissection in ice-cold artificial cerebral spinal fluid (aCSF)
(in mM: 120 NaCl, 3.5 KCl, 2.5 CaCl2, 1.3 MgSO4, 1.25
NaH2PO4, 26 NaHCO3, and 10 D-glucose, saturated with
95% O2 and 5% CO2). Slices were then cut with a vibrating
blade microtome (VT 1000s, Leica, Bannockburn, IL) into
transverse, 400μm thick slices. Hippocampi were dissected
out and moved into a holding chamber containing oxygen-
ated aCSF and allowed to recover for at least an hour at room
temperature. For experiments with picrotoxin and Aβ oligo-
mers, hippocampal slices were placed in the recording cham-
bers soon after this recovery period. For experiments with
memantine, half of the slices stayed in the original holding
chamber and half were moved to a second holding chamber
with oxygenated aCSF containing 1, 3, or 10μMmemantine.
In these experiments, both sets of hippocampal slices were
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maintained in their respective holding chambers for an addi-
tional 4 hours before being placed in the recording chamber.
2.3. Drug and Experimental Compounds. Stock solutions of
memantine (Sigma, St. Louis, MO) were dissolved in stan-
dard aCSF (see above) at 1, 3, or 10mM, stored at −80°C until
the day of experiments, and diluted 1 : 1000 to a final concen-
tration of 1, 3, or 10μM on the day of experiments. For the
two lowest concentrations of picrotoxin (Sigma) used here
(0.1 and 1μM), 10x stock solutions were prepared (1 and
10μM, resp.) and diluted to the appropriate concentration
on the day of the experiment. Given that picrotoxin does
not dissolve in water at high concentrations, 10 and 100μM
were dissolved in aCSF on the day of the experiment. Bacte-
rial expression and purification of rPrP were performed as
described previously [29], and the protein concentration
was determined by measuring absorbance at 276nm using
the appropriate extinction coefficients.
2.4. Preparation of Aβ Oligomers and rPrP. Preparation of
Aβ1-42 oligomers (referred to, throughout the text, as Aβ
oligomers) and rPrP has been previously described [30].
Briefly, human Aβ1-42 (rPeptide, LLC, Bogart, GA) was sol-
ubilized in hexafluoro-2-propanol, divided into aliquots, and
after solvent evaporation, was stored at −80°C. Immediately
before use, the peptide was dissolved in 10mM NaOH, into
a concentration of 400μM, and subjected to 10 cycles of
10-second sonication on ice to remove any residual aggre-
gates. Disaggregated Aβ was diluted in 10mM sodium phos-
phate, pH7.4, to a concentration of 100μM. To prepare
soluble Aβ oligomers, the peptide (20μM) was incubated in
50mM sodium phosphate buffer, pH7.4, for 3 hours at
37°C. Once every 20 minutes, the plates were subjected to
shaking for 10 seconds. As shown previously, these experi-
mental conditions result in Aβ preparations that are highly
enriched in soluble oligomers [30]. Finally, rPrP was added
to freshly disaggregated Aβ and these mixtures were incu-
bated as described above for Aβ alone.
2.5. Electrophysiology. Parallel recordings of treated (meman-
tine, picrotoxin, Aβ oligomers, rPrP, or Aβ oligomers + rPrP)
and untreated hippocampal slices from the same animal were
performed using a customized electrophysiology setup. In all
experiments, one hippocampal slice was used per animal per
condition. Field excitatory postsynaptic potentials (fEPSPs)
were recorded with Ag/AgCl recording electrodes through
thin-walled, 1.5mm, WPI borosilicate glass micropipettes
filled with aCSF (3–5MΩ resistance), inserted into the CA1
region of the hippocampus. Two fine bipolar platinum/irid-
ium electrodes (FHC, Bowdoinham, ME) were positioned
on the CA1 Schaffer collateral fibers at opposite sides of the
recording pipette. Stimulation intensity was adjusted to 40–
50% of the amplitude that is required to produce population
spikes. For experiments probing the effects of memantine or
picrotoxin, a stable baseline of synaptic transmission was
established for 20 minutes prior to the induction of LTP or
L-LTP. LTP was induced by high-frequency stimulation
(HFS; 100Hz for 1 s), theta-burst stimulation (TBS; 5 trains
of 4 pulses at 100Hz, 200ms intertrain interval), or four
stimulus trains (4xHFS; with a 5-minute intertrain interval)
in the CA1 region of the hippocampus in Ts65Dn- and
euploid control-derived hippocampal slices. In some 4xHFS
LTP experiments, we quantified the mean levels of early-
phase LTP (E-LTP) at 60 minutes and/or late-phase LTP
(L-LTP) at 180-minute poststimulation. To assess the poten-
tial modulatory effects of Aβ oligomer on 4xHFS-induced
LTP in Ts65Dn-derived and euploid control-derived hippo-
campal slices, a stable baseline of synaptic transmission was
established for 10 minutes before the bath application of
Aβ oligomers (500 nM) alone or Aβ (500 nM) mixed with
rPrP (100 nM). While slices were superfused with these test
molecules, a second stable synaptic transmission baseline
was established for 10 minutes prior to induction of LTP by
4xHFS. Bath perfusion of the test molecules continued for
10 minutes after LTP induction. To reduce the use of Aβ olig-
omers, aCSF was recirculated during this time.
Signals from the recording electrode were amplified
1000 times (Brownlee Precision Electrophysiology Ampli-
fier Model 440, San Jose, CA), low-pass filtered (8-pole
Bessel) at 2 kHz, and digitized at 20 kHz by a Digidata
digitizer (1322A, Axon Instruments) into a Microsoft
Windows-based computer. PCLAMP software (PCLAMP
8.2, Axon Instruments) was used for data acquisition and
offline data analysis.
2.6. Statistics. Synaptic efficacy was determined by the slope
of fEPSPs normalized to the mean value of fEPSP slopes
recorded prior to the induction of LTP or L-LTP. Compari-
sons between mean levels of LTP in slices from the two geno-
types investigated (Ts65Dn and euploid control), subjected to
1μMmemantine, were done by two-way analysis of variance
(ANOVA) (Statistica, version 12, Dell Inc., Tulsa, OK). Sim-
ple comparisons between the mean levels of 4xHFS-induced
LTP at 60-minute and 180-minute poststimulation in slices
from the two genotypes were assessed using two-tailed
unpaired t-tests with Welch’s correction (GraphPad Prism
7.0, GraphPad Software Inc., San Diego, CA, USA). Compar-
isons of mean levels of L-LTP in slices in a given genotype for
three different pharmacological treatments (memantine, pic-
rotoxin, and aβ oligomers + rPrP) were done by one-way
ANOVA (Statistica). Comparisons of mean normalized levels
of L-LTP between the two genotypes, when subjected to pro-
gressively higher levels of memantine or picrotoxin, were per-
formed by repeated measures ANOVA (RM-ANOVA)
(Statistica). Comparisons of mean normalized levels of
4xHFS-induced E-LTP between the two genotypes, when
subjected to aβ oligomers, rPrP, or aβ oligomers + rPrP, were
performed by two-way ANOVA (Statistica). When ANOVA
detected either a main factorial effect or an interaction
between factors, it was followed by post hoc multiple com-
parisons using the Fisher’s least significant difference
(LSD) (Statistica). For all comparisons, a “p” value of <0.05
was selected as the criterion for statistical significance.
3. Results
3.1. The Effects of Memantine on HFS- and TBS-Induced LTP.
In this subsection, we describe the results of experiments in
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which we compared levels of HFS-induced and TBS-induced
CA1 LTP in Ts65Dn- and euploid control-derived untreated
slices versus slices treated with 1μM memantine. For HFS-
induced LTP, in agreement with the previous work [14], we
found no significant difference between levels of LTP in slices
from Ts65Dn mice compared with those from euploid litter-
mate control mice (Figures 1(a) and 1(c)). In addition, we
found that treatment with 1μM memantine did not signifi-
cantly alter the induction or maintenance of this form of
LTP in either Ts65Dn or euploid littermate control-derived
slices (Figures 1(a) and 1(c)). Two-way ANOVA failed to
detect any significant genotype (F(1,40) = 1.058, p = 0 31) or
treatment (F(1,40) = 0.030, p = 0 86) effect, or any interaction
between genotype and treatment (F(1,40) = 0.0084, p = 0 93).
For TBS-induced LTP, our results were also in agreement
with the previous work, with Ts65Dn-derived slices display-
ing decreased LTP levels in relation to those from euploid
control mice (Figures 1(b) and 1(d)). In addition, we found
that 1μM memantine increased the mean level of TBS-
induced LTP in Ts65Dn-derived slices to that recorded in
euploid control slices. Although, two-way ANOVA detected
no significant genotype (F(1,50) = 2.12, p=0.15) or treatment
(F(1,50) = 0.019, p = 0 89) effect, there was a significant geno-
type× treatment interaction (F(1,50) = 7.69, p = 0 0078).
Accordingly, post hoc analysis indicated that untreated
Ts65Dn-derived slices had a decreased mean level of LTP
when compared with untreated euploid control-derived
slices (p = 0 0049) and with memantine-treated Ts65Dn-
derived slices (p = 0 041). Additionally, post hoc analysis
showed that the mean level of LTP in memantine-treated
Ts65Dn-derived slices was not significantly lower than
untreated euploid control-derived slices (p = 0 35).
3.2. The Effects of Memantine on L-LTP. Here, we describe
the effects of memantine on L-LTP induced by 4xHFS.
Because this specific form of LTP had not yet been character-
ized in Ts65Dn mice, we first compared the mean level of
LTP in Ts65Dn-derived hippocampal slices with that in
euploid control slices. In these experiments, we observed
reduced levels of L-LTP in slices from Ts65Dn mice when
compared with those of euploid control mice at both
60min and 180min after LTP induction (Figure 2(a)).
Unpaired Student t-test comparisons of the mean levels of
LTP showed a significant difference between control-
(234.70± 13.43; n = 16) and Ts65Dn-derived hippocampal
slices (186.30± 11.20; n = 15) (t = 2 77; df = 28.4; p = 0 0097)
at 60min after LTP induction (Figure 2(b)). Such genotype-
dependent significant difference in mean levels of LTP per-
sisted even at 180min after LTP induction (Figure 2(b))
(174.70± 8.50; N = 16; and 142.20± 8.50; N = 15; for euploid
control- and Ts65Dn-derived slices, resp.) (t = 2 70;
df = 28.97; p = 0 011).
We then investigated the potential effects of meman-
tine treatment on 4xHFS-induced L-LTP in Ts65Dn and
euploid control slices. We used three concentrations of
memantine (1, 3, and 10μM) to assess the concentration
dependence of any potential effect of this drug
(Figures 3(a) and 3(b)). Similar to the HFS-induced LTP
and TBS-induced CA1 LTP, both Ts65Dn- and euploid
control-derived hippocampal slices were pretreated with the
appropriate concentration of memantine 4 h before the start
of the recording session. RM-ANOVA indicated that mem-
antine (which was also continuously bath-perfused during
the recording sessions) significantly inhibited the induction
of L-LTP in euploid control-derived slices (F(3,45) = 11.55,
p = 0 00001) (Figure 3(c)), but did not significantly affect the
induction of L-LTP in Ts65Dn-derived slices (F(3,42) = 1.40,
p = 0 26) (Figure 3(d)). Post hoc analysis indicates that
memantine significantly decreased the level of L-LTP induced
in euploid control-derived slices at the concentrations of 3μM
(p = 0 00011) and 10μM (p = 0 000007) (Figure 3(c)).
Therefore, in contrast to TBS-induced LTP, 1μM meman-
tine did not increase the mean level of L-LTP seen in
Ts65Dn slices, however, this drug still had a genotype-
dependent effect by not reducing the levels of L-LTP in
Ts65Dn slices (Figure 3(d)).
As an alternative means of visualizing the genotype-
dependent effects of memantine on L-LTP mentioned in
the previous paragraph, the data was normalized to the
untreated genotype-specific levels. (In other words, the mean
L-LTP levels in both euploid control- and Ts65Dn-derived
untreated slices were set as 100% and the mean L-LTP levels
for memantine-treated slices were obtained by dividing the
LTP level for each concentration of memantine by its
genotype-specific untreated levels and multiplying the result
by 100.) As suspected, RM-ANOVA of the resulting data
unveiled a significant genotype (F(1,18) = 9.58, p = 0 0062)
and dose (F(3,54) = 6.12, p = 0 0012) dependence. However,
no significant dose× genotype interaction was found
(F(3,54) = 2.41, p = 0 078). Here again, post hoc analysis
showed that memantine at the doses 3μM (p = 0 0091)
and 10μM (p = 0 036) reduced the level of L-LTP induced
in euploid control-derived slices, but not in Ts65Dn-
derived slices.
3.3. High Doses of Picrotoxin Increase the Levels of L-LTP in
Ts65Dn-Derived Slices. Kleschevnikov et al. [13] have
shown that reduced levels of HFS-induced LTP in the
dentate gyrus of Ts65Dn mice can be pharmacologically
enhanced by the antagonism of gamma-aminobutyric acid
receptor type A (GABAA)-mediated synaptic inhibition with
picrotoxin. A similar effect of picrotoxin has also been shown
on CA1, TBS-induced LTP in Ts65Dn-derived hippocampal
slices [14].
Here, we tested the effects of 0.1, 1, 10, and 100μMpicro-
toxin on the levels of CA1L-LTP in bothTs65Dn- and euploid
control-derived hippocampal slices (Figures 4(a)–4(d)). At
these concentrations, picrotoxin did not significantly affect
the mean levels of L-LTP in euploid control-derived slices
(F(4,48) = 1.69, p = 0 17) (Figure 4(c)), but significantly
increased the mean levels of L-LTP in Ts65Dn-derived slices
(F(4,45) = 3.45, p = 0 015) (Figure 4(d)). Post hoc analysis, how-
ever, revealed that picrotoxin only produced significant
increases in themean level of L-LTP in Ts65Dn-derived slices
at the two highest concentrations, that is, 10μM (p = 0 0046)
and 100μM (p = 0 00995) (Figure 4(d)).
In the same way that was done in the analysis of the pre-
vious experiment with memantine, data was normalized to
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Figure 1: The effects of 1μMmemantine on HFS- and TBS-induced LTP in hippocampal slices from Ts65Dn and euploid control mice. (a)
Normalized fEPSP slopes of HFS-induced LTP and (b) TBS-induced LTP. Magnification of the last 10 minutes of recording. Colored lines
represent the calculated mean fEPSP slopes for the last 10 minutes of recording. (c, d) Summary graph representation of the LTP data
(mean fEPSP slope during the last 10min of recording for each hippocampal slice). When used at the therapeutically relevant
concentration of 1 μM, memantine did not alter the induction or maintenance of HFS-induced LTP but it rescued TBS-induced LTP to
control euploid levels in slices from Ts65Dn mice. p < 0 05 and p < 0 01 are represented by ∗ and ∗∗, respectively. Number of slices
(animals) for HFS (Ct w/o Mem (n = 11), Ct Mem (n = 11), Ts w/o Mem (n = 11), and Ts Mem (n = 11)) and TBS (Ct w/o Mem
(n = 13), Ct Mem (n = 13), Ts w/o Mem (n = 13), and Ts Mem (n = 15)). Error bars represent SEM. Arrow indicates LTP induction,
representative traces show synaptic response during baseline (1) and at end of recording (2). Scale bars represent 1mV (horizontal) and
10ms (vertical).
5Neural Plasticity
the untreated genotype-specific levels (Figure 4(e)) as an
alternative way to evaluate whether there was a genotype
dependence for the picrotoxin effects. A RM-ANOVA
showed significant genotype (F(1,16) = 6.24, p = 0 024) and
dose (F(4,64) = 3.58, p = 0 011) effects, however, no significant
interaction between dose and genotype was detected
(F(4,64) = 1.13, p = 0 35). Post hoc analysis showed that only
100μM picrotoxin produced a relatively greater response in
Ts65Dn-derived slices when compared with euploid control
slices (p = 0 040).
In Figures 4(a) (right panel) and 4(b) (right panel), we
illustrate that the same concentrations of picrotoxin (10
and 100μM) that significantly enhance the levels of L-LTP
in Ts65Dn mice also produce significant seizure-like oscilla-
tions in both pre- and posttetanic fEPSPs. Additionally, post-
tetanic fEPSPs displayed significant network oscillations at
concentrations of picrotoxin as low as 1μM in Ts65Dn-
and euploid control-derived slices.
3.4. Effects of Aβ and rPrP on 4xHFS-Induced LTP in
Ts65Dn-Derived Hippocampal Slices. Soluble Aβ oligomers
are potent synaptotoxins that have been shown to inhibit
4xHFS-induced LTP in the CA1 region of the hippocampus
[31, 32]. Recently, Scott-McKean et al. [30] have shown that
soluble rPrP and its N-terminal fragment N1 block this Aβ
oligomer-induced inhibition of 4xHFS-induced E-LTP.
In agreement with the work of Scott-McKean et al. [30],
we found that superfusion of euploid control-derived hippo-
campal slices with Aβ oligomers (500 nM) produced a
noticeable inhibition of 4xHFS-induced LTP (Figures 5(a)
and 5(c)) in relation to untreated slices from these same
animals. Furthermore, when slices were exposed to Aβ
(500 nM) mixed with rPrP (100 nM), this inhibition was sup-
pressed (Figure 5(c)), which is reflected by the statistically
significant treatment effect observed (F(3,41) = 4.31, p =
0 0099). Post hoc analysis indicated that Aβ oligomers sig-
nificantly decreased the level of 4xHFS-induced LTP in
euploid control-derived slices (p = 0 0015) (Figure 5(c))
and that soluble rPrP restored the mean level of LTP to a
value statistically indistinguishable from that of untreated
slices (p = 0 60). Unlike in control-derived hippocampal
slices, however, there was little to no effect of Aβ oligomers
on the induction of 4xHFS-induced LTP in Ts65Dn-derived
slices (Figures 5(b) and 5(d)). Indeed, a one-way ANOVA
found no significant treatment effect with Aβ, soluble rPrP,
or Aβ plus rPrP on the mean levels of 4xHFS-induced LTP
in Ts65Dn-derived slices (F(3,47) = 2.51, p = 0 070).
We then compared directly the mean level of LTP in
control slices with those of untreated and treated Ts65Dn-
derived slices. To this end, we performed the comparison
illustrated in Figure 5(e) and an additional ANOVA, which
produced a quantitative measure of statistical significance
of the observed differences in 4xHFS-induced LTP
(F(3,49) = 6.17, p = 0 0012). Post hoc analysis showed signifi-
cantly decreased levels of 4xHFS-induced LTP in untreated
Ts65Dn-derived slices (p = 0 0084), Aβ oligomer-treated
Ts65Dn-derived slices (p = 0 00014), and rPrP-treated
Ts65Dn-derived slices (p = 0 0051) when compared to
euploid hippocampal slices.
Finally, data was normalized once again to the untreated
genotype-specific levels (Figure 5(f)). A two-way ANOVA
detected significant genotype (F(1,87) = 4.87, p = 0 030) and
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Figure 2: Ts65Dn hippocampal slices show reduced 4xHFS-induced LTP compared with slices from euploid control mice. (a) Comparisons
of 4xHFS-induced L-LTP on euploid control-derived slices versus Ts65Dn-derived slices at 60min and 180min after induction. (b) Summary
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treatment (F(3,87) = 6.79, p = 0 00036) effects, but no signifi-
cant interaction between treatment and genotype
(F(3,87) = 1.20, p = 0 32). Post hoc analysis confirmed that
control-derived slices displayed a greater inhibition to
4xHFS-induced LTP by Aβ oligomers when compared with
Ts65Dn-derived slices (p = 0 00029).
4. Discussion
In this study, we examined three representative modalities of
LTP in the CA1 region of hippocampal slices obtained from
the Ts65Dn mouse model of DS. The first goal of this study
was to test the hypothesis that a therapeutically relevant
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Figure 3: The effects of memantine on L-LTP. (a) Comparison of the effects of memantine (1, 3, and 10μM) on 4xHFS-induced L-LTP in
euploid control-derived slices and (b) Ts65Dn-derived slices. Magnification of the final 10 minutes of recording. Colored lines represent
the mean fEPSP slopes calculated for the last 10 minutes of recording. (c) Summary graph of euploid littermate control L-LTP data and
(d) Ts65Dn L-LTP data (mean fEPSP slope during the last 10min for each recording condition). Memantine at 3 and 10 μM blocked the
induction of L-LTP in euploid control slices and had no effect on Ts65Dn-derived slices. (e) Normalized data shows a greater inhibited L-
LTP in euploid control slices at 3 and 10μM when compared to Ts65Dn slices. p < 0 05, p < 0 01, and p < 0 001 are represented by ∗, ∗∗,
∗∗∗, respectively. Number of slices (animals) for control (without mem (n = 16), mem 1μm (n = 13), mem 3μm (n = 10), and mem 10 μm
(n = 10)) and Ts65Dn (without mem (n = 15), mem 1μm (n = 11), mem 3 μm n = 10, and mem 10 μm (n = 10)). Error bars represent
SEM. Arrows indicates LTP induction (4xHFS; with a 5min intertrain intervals), representative traces show synaptic response during
baseline (1) and at end of recording (2). Scale bars represent 1mV (horizontal) and 10ms (vertical).
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Figure 4: Dose dependence of the effects of picrotoxin on L-LTP induced by 4xHFS. (a) Comparisons of the effects of picrotoxin (0.1, 1, 10,
and 100μM) on 4xHFS-induced L-LTP in euploid control-derived slices and (b) Ts65Dn-derived slices. Magnification of the final 10 minutes
of recording. Colored lines represent the mean fEPSP slopes calculated for the last 10 minutes of recording. Representative fEPSP traces
showing severe oscillations recorded from control-derived slices and Ts65Dn-derived slices after being exposed to picrotoxin. (c)
Summary graph of euploid littermate control L-LTP data and (d) Ts65Dn L-LTP data (mean fEPSP slope during the last 10min for each
recording condition). 10 and 100μM of picrotoxin rescued L-LTP to control levels in Ts65Dn-derived slices while causing severe
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concentration of memantine (1μM) [33] might interfere
negatively with the induction and/or maintenance of LTP,
and, by extension, with fundamental cellular mechanisms
underlying learning and memory in these animals. We had
to consider this hypothesis because of all accumulated evi-
dence that the proper function of NMDA receptors is critical
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Figure 5: Aβ oligomers inhibit 4xHFS-induced LTP in euploid slices (but not Ts65Dn slices) and rPrP suppresses this inhibition. (a, b)
Normalized fEPSP slopes in the presence or absence of Aβ oligomers alone or Aβ mixture with rPrP from euploid control-derived slices
(a) or Ts65Dn-derived slices (b). Magnification of the final 10 minutes of recording. Colored lines represent the calculated mean fEPSP
slopes for the last 10 minutes of recording. (c, d) Mean fEPSP slopes during the last 10min of fEPSP recordings derived from data shown
in panels (a) and (b), respectively. In Ts65Dn-derived slices, which already shows a deficit in 4xHFS-induced L-LTP when compared to
euploid controls, Aβ oligomers had no further effect on L-LTP. rPrP rescued Aβ oligomer-induced inhibition 4xHFS-induced LTP in
control slice; however, rPrP alone had no effect on 4xHFS-induced LTP in Ts65Dn-derived slices. (e) Shows that the levels of LTP in
untreated control slices is significantly larger than the levels of LTP observed in Ts65Dn mouse slices under any treatment. (f) Relative
decrease in 4xHFS-induced LTP due to Aβ oligomer-induced inhibition. Euploid control slices showed greater inhibition due to Aβ
oligomers when compared to Ts65Dn-derived slices. p < 0 05, p < 0 01, and p < 0 001 is represented by ∗, ∗∗, ∗∗∗, respectively. Number of
slices (animals) for control (aCSF (n = 14), Aβ (n = 10), rPrP (n = 11), and Aβ mixture with rPrP (n = 10)) and Ts65Dn (aCSF (n = 14),
Aβ (n = 13), rPrP (n = 12), and Aβ mixture with rPrP (n = 12)). Error bars represent SEM. Arrows indicates LTP induction (4xHFS; with
a 5min intertrain intervals), representative traces show synaptic response during baseline (1) and at end of recording (2). Scale bars
represent 1mV (horizontal) and 10ms (vertical). Horizontal black bar indicate aCSF, Aβ, rPrP, or Aβ mixture with rPrP.
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for the induction of LTP [34–36]. There was also previous
work demonstrating that the same concentration of mem-
antine rescues the exaggerated levels of NMDA receptor-
dependent CA1 LTD in Ts65Dn mice by reducing the
mean levels of this form of synaptic plasticity [17]. In light
of preclinical and clinical work underway aimed at testing
this NMDA receptor antagonist as a potential pharmaco-
logical intervention to enhance the cognitive abilities of
individuals with DS, this issue has assumed particular
importance, given that an inhibitory action of memantine
on LTP could potentially translate into undesirable clinical
effects of this drug.
Here, it is important to notice that, although meman-
tine’s mechanism of action is generally assumed to primarily
due to its antagonism of NMDA receptor channels, it should
be noted that, because memantine also binds to a number of
other receptors, a few alternative mechanisms for its action
have been proposed. For example, Moriguchi et al. [37] pro-
posed that ATP-sensitive K+ (KATP) channels are potentially
relevant targets for memantine action in the treatment of AD.
For the two forms of CA1 LTP that had already been
investigated in Ts65Dn mice, our results from untreated
slices were consistent with previous reports [14, 38–40]. We
found no significant difference in the mean levels of HFS-
induced LTP between Ts65Dn- and euploid control-derived
slices, whereas a small but significant reduction in the mean
level of TBS-induced LTP was observed in Ts65Dn mouse-
derived slices compared with that of euploid control animals.
Contrary to our working hypothesis, however, we found that
memantine not only had no inhibitory effect on LTP induced
by HFS, but it actually rescued the deficit in TBS-induced
LTP in Ts65Dn mice. Indeed, this pharmacological rescue
of TBS-induced LTP may be, in addition to the rescue of
exaggerated levels of NMDA-dependent LTD, another elec-
trophysiological correlate of memantine’s memory and
learning enhancing effects in Ts65Dn mice.
In addition to the HFS- and TBS-induced modalities of
LTP, we also assessed CA1 LTP induced by 4xHFS, which
is a form of stimulation capable of producing the highly
durable form of synaptic plasticity known as L-LTP. In
addition to requiring gene transcription and protein syn-
thesis in the postsynaptic neuron, this form of LTP is reg-
ulated by the activity of the regulator of calcineurin 1,
RCAN1 (also known as Down syndrome critical region 1
(DSCR1)) [41], which is a gene product of chromosome
21 whose orthologue is also located in the Ts65Dn chro-
mosome. This observation was critical in motivating the
assessment of L-LTP in Ts65Dn mice here, given that dys-
function of NMDA receptors in DS was originally theoret-
ically predicted as the potential consequence of the
inhibition of calcineurin activity due to overexpression of
chromosome 21 gene products such as RCAN1 and
DYRK1A (perhaps coupled to elevated amounts of reactive
oxidative species) [42]. Therefore, the finding of reduced
levels of CA1 LTP induced by 4xHFS recorded at both
early phase and late phase in hippocampal slices from
Ts65Dn when compared with similar recordings made
from euploid littermate control-derived slices was both
an almost predictable finding and a key piece of the puzzle
toward a better understanding of DS pathophysiology at
the synaptic level.
The uncomplicated argument that one can make for the
observed genotype dependence of LTP induced by 4xHFS
would be that calcineurin activity might have an inverse U-
shaped effect on L-LTP. This would mean that in both
Ts65Dn and RCAN1 knockout mice, dysregulated levels of
calcineurin activity might produce suboptimal levels of L-
LTP. However, if such effect was the result of alterations in
NMDA receptor function, the expectation would be that
memantine might also pharmacologically rescue these
lower-than-control levels of synaptic potentiation. Instead,
we found that memantine, even when superfused at a level
10 times higher than the therapeutically relevant concentra-
tion of 1μM, had no significant effect on the mean level
4xHFS-induced LTP in Ts65Dn mouse-derived slices. We
also found that, although memantine at a concentration of
1μM had no effect on L-LTP in control-derived slices, at 3
and 10μM, it started to inhibit this form of LTP in slices from
euploid mice. In its own way, this differential, genotype-
dependent effect of memantine on L-LTP provides additional
support to the hypothesis that NMDA receptor function is
altered in this mouse model of DS. However, instead of being
more susceptible to undesirable effects of potentially toxic
doses of memantine, as far as inhibition of L-LTP goes,
Ts65Dn mice have shown to be more resistant to high doses
of memantine than euploid control mice.
Given that this was the first exploration of the properties
of 4xHFS-induced LTP in Ts65Dn mice, the second goal of
this study was to quantify the effects of a few additional mol-
ecules of interest to the study of DS that could potentially
shed some light on this specific form of LTP in Ts65Dn mice.
These molecules were (1) picrotoxin; (2) Aβ oligomers; and
(3) soluble rPrP.
The idea that the inhibition of GABAA receptors could
enhance LTP in brain slices from Ts65Dn mice was first
explored by Kleschevnikov et al. [13], who showed that
100μM picrotoxin can increase the mean levels of LTP
in the dentate gyrus to the same level as those in slices
from euploid control mice. A similar effect was then
described by Costa and Grybko [14], who demonstrated
that 10μM picrotoxin could also elevate the mean level
of TBS-induced CA1 LTP in Ts65Dn-derived slices to
those seen in euploid control-derived slices. Subsequently,
work by Fernandez et al. [43] showed that Ts65Dn mice
treated with a chronic, 2-week daily regimen of the sub-
convulsive dose of 1mg/kg picrotoxin intraperitoneally
(i.p.) displayed a durable enhancement in object recogni-
tion performance. This i.p. dose of picrotoxin (which is a
1 : 1 molecular complex of picrotin and picrotoxinin) in
the rat (data is not available in the mouse) translates into
peak serum levels of ≈2μM of picrotin and picrotoxinin,
which are reached in ≈30min and rapidly decay to base-
line levels in ≈60min [44].
In the present study, we assessed the effects of 0.1, 1,
10, and 100μM of picrotoxin on 4xHFS-induced CA1 L-
LTP in Ts65Dn-derived hippocampal slices. We found
that picrotoxin produced significantly increases in the
mean level of L-LTP in Ts65Dn-derived slices at 10 and
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100μM, but not at lower concentrations. However, these
increases in the mean levels of LTP were also accompa-
nied by high-amplitude 200–250Hz network oscillations
in slices of both genotypes, which could be detected before
and after LTP induction (see analysis of oscillations in
Supplementary Data available here). Therefore, given these
seizure-like oscillations produced by high doses of picro-
toxin, the term “pharmacological rescue” of the LTP levels
can hardly be applied to this treatment. Indeed, 10μM
picrotoxin is similar to the peak serum levels of this com-
pound that are achieved after typical seizure-inducing
doses of 3–5mg/kg i.p. [44, 45]. To date, the positive
effects on memory and learning performance found after
a chronic regimen of the subconvulsive doses of picrotoxin
in Ts65Dn mice remain unexplained, but are unlikely to
be due to acute enhancements in the levels of any form
of CA1 LTP. This same line of reasoning is also likely to
apply to other modulators of GABAA receptors, such as
pentylenetetrazole or RG1662.
This pharmacological survey of the properties of 4xHFS-
induced CA1 E-LTP in Ts65Dn-derived hippocampal slices
concluded with the investigation of the effects of Aβ oligo-
mers and soluble rPrP. The obvious reason to probe the
effects of Aβ oligomers on LTP induced by 4xHFS in
Ts65Dn-derived slices was that the amyloid precursor pro-
tein gene, APP (which encodes the protein from which Aβ
peptides originate), is present in three copies in persons with
DS and Ts65Dn mice. Indeed, trisomy of APP is thought to
be a necessary molecular factor underlying the virtually uni-
versal incidence of AD-type pathology in persons with DS
aged 40 year and beyond [46]. Additionally, different stud-
ies have demonstrated that Aβ oligomers can inhibit
4xHFS-induced LTP in the CA1 region of the hippocam-
pus [30–32]. These findings made it particularly attractive
to investigate the effects of Aβ oligomers in Ts65Dn mice,
which are likely to be constitutively exposed to higher-
than-typical levels of these oligomers.
We had two competing hypotheses in designing the
experiments involving the effects of Aβ oligomers and solu-
ble rPrP on 4xHFS-induced CA1 E-LTP. First hypothesis:
4xHFS-induced CA1 LTP in hippocampal slices from
Ts65Dn mice would be more sensitive to Aβ oligomers than
in slices from euploid control mice due to the additive effects
of exogenous and endogenous Aβ oligomers. Second hypoth-
esis: 4xHFS-induced CA1 LTP would be less sensitive in
slices from Ts65Dn mice versus those from euploid control
animals, due to compensatory developmental mechanisms.
In the same vein of thought, the use of soluble rPrP allowed
us to interrogate directly whether the reduced levels of
4xHFS-induced CA1 LTP observed in Ts65Dn-derived slices
were directly due to effect of elevated endogenous Aβ oligo-
mers in the brains of these animals, given that this molecule
is known to block the Aβ oligomer-induced inhibition of
LTP [30].
Our results showing that Aβ oligomers cause substan-
tially stronger inhibition of 4xHFS-induced LTP in control-
derived slices when compared with Ts65Dn-derived slices
are consistent with the second hypothesis, suggesting that
hippocampi in Ts65Dnmicemight have developed resistance
to exogenous Aβ oligomers, likely due to compensatory
developmental mechanisms. Whether these mechanisms are
in any way related to a potential long-term exposure to ele-
vated levels of endogenous Aβ remains to be determined.
Nevertheless, the present data clearly indicate that the intrin-
sically depressed level of LTP in Ts65Dn-derived slices can-
not be rescued by rPrP, a protein that blocks the exogenous
Aβ oligomer-mediated inhibition of LTP in slices from
euploid control animals.
As pointed out in the introduction of this research article,
the quantification of 4xHFS-induced LTP can be seen as an
informative assay of the integrity of the essential transcrip-
tional and translational machinery in neurons from different
mouse models of neurological and psychiatric disorders.
Therefore, the findings regarding this form of LTP in Ts65Dn
that we presented here have important consequences from
both basic and translational points of view. From the basic
science aspect, it describes an animal model of a human dis-
order in which the integrity of transcription and/or transla-
tion is compromised and provides a new useful tool for
future in depth research in these areas in mouse and human
cell-based models of DS. From the translational perspective,
it is somewhat refreshing to see a phenotype in Ts65Dn that
is resistant to pharmacological intervention. Recent reviews
of preclinical studies in Ts65Dn mice have described more
than a dozen pharmacological or nutritional interventions
that have rescued electrophysiological and/or behavioral
phenotypes [9]. However, even for compounds or drugs for
which we have had solid, reproducible, and powerful effects
in the mouse, such as memantine, small scale clinical
research in human beings, although promising, have shown
at best mild-to-moderate effect sizes in very specific domains
of cognition. Therefore, revisiting some of the historically
successful preclinical agents used in Ts65Dn mice with
4xHFS-induced LTP (as we have done here for meman-
tine, picrotoxin, and rPrP) may reveal a more nuanced
picture in which many of those agents may have no effect,
some may have negative effects and some may rescue this
synaptic plasticity phenotype without causing seizure-like
network oscillations.
In recent years, there has been a growing availability of
new mouse models of DS, some of which were designed to
address the shortcomings of the Ts65Dn mouse model
(for reviews see [9, 10]). These shortcomings include: (1)
incompleteness of the set of chromosome 21 orthologous
genes triplicated in the Ts65Dn marker chromosome and
(2) unspecificities in the set of genes contained in the
Ts65Dn trisomic segment. A frequently cited unspecificity
is that Ts65Dn mice are also trisomic for a >5.8Mb sub-
centromeric region on mouse chromosome 17 (which con-
tains at least 50 genes) that is not orthologous to any
region on human chromosome 21 [47]. Another unspecifi-
city comes from the fact that the Ts65Dn trisomic
segment includes many mouse-specific genes not repre-
sented in the human genome. In this context, the present
study provides a necessary baseline for a new LTP pheno-
type that can be explored in future studies involving neu-
ral plasticity in these newer and emerging mouse models
of DS, including overexpressing single gene models such
11Neural Plasticity
as Girk2, App, Dyrk1a, Rcan1, and Olig2 transgenic mice.
In addition, correction of gene copy number for some of
these genes, which are present in three copies in Ts65Dn
mice, has been shown to result in the correction of some
forms of synaptic plasticity alteration in these animals.
5. Conclusions
In this study, we learned that both E-LTP and L-LTP induced
by 4xHFS were significantly depressed when compared with
these same forms of LTP in euploid control slices. In addi-
tion, the drug memantine, when used at the pharmacologi-
cally relevant concentration of 1μM, had no detectable
effect on HFS LTP or 4xHFS-induced L-LTP in the mouse
model of DS Ts65Dn or control-derived slices, but this same
concentration of memantine rescued TBS LTP in Ts65Dn-
derived slices to control euploid levels. Therefore, at thera-
peutic levels, memantine produces no adverse effects on the
induction or maintenance of LTP in hippocampal slices from
Ts65Dn mice and actually enhances the levels of one modal-
ity of LTP in slices from this mouse model of DS. We also
investigated the effects of picrotoxin, amyloid beta oligomers,
and soluble (membrane anchor-free) recombinant human
rPrP on this specific form of LTP. Whereas 10μM and
100μM of picrotoxin increased the mean levels of L-LTP in
Ts65Dn-derived slices to values comparable to those in
euploid control slices, these concentrations of picrotoxin also
produced seizure-like oscillations in postsynaptic potentials.
Hence, this (and previously reported) pharmacologically
induced enhancements on the levels of LTP in Ts65Dn mice
cannot be called a true pharmacological rescue, given that
any potential benefit of such high levels of GABAA receptor
inhibition would be offset by the induction of seizures.
Finally, amyloid beta oligomers did not significantly inhibit
the levels of 4xHFS-induced E-LTP in Ts65Dn-derived slices,
and rPrP alone had no effect on E-LTP on either Ts65Dn-
derived or euploid control-derived slices.
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